tiprankstipranks
PW Medtech Group Ltd. (DE:PWE)
BERLIN:PWE

PW Medtech Group Ltd. (PWE) Income Statement

0 Followers

PW Medtech Group Ltd. Income Statement

Last quarter (Q2 2022), PW Medtech Group Ltd.'s total revenue was ¥―, a decrease of ― from the same quarter last year. In Q2, PW Medtech Group Ltd.'s net income was ¥―. See PW Medtech Group Ltd.’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
-¥ 271.40M¥ 247.35M¥ 362.18M¥ 310.81M¥ 286.91M
Cost of Revenue
-¥ 105.34M¥ 98.75M¥ 140.06M¥ 115.57M¥ 112.39M
Gross Profit
-¥ 166.06M¥ 148.60M¥ 222.13M¥ 195.24M¥ 174.53M
Operating Expense
-¥ 135.97M¥ 183.72M¥ 184.07M¥ 148.38M¥ 129.95M
Operating Income
-¥ 30.09M¥ -35.12M¥ 38.05M¥ 46.87M¥ 44.58M
Net Non Operating Interest Income Expense
-¥ 56.73M¥ -5.13M¥ -28.50M¥ -7.21M¥ 1.77M
Other Income Expense
------
Pretax Income
-¥ 737.46M¥ 626.60M¥ 85.81M¥ 126.58M¥ 45.08M
Tax Provision
-¥ -1.65M¥ -5.21M¥ 3.84M¥ 11.06M¥ 11.30M
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
-¥ 739.12M¥ 631.81M¥ 81.98M¥ 1.67B¥ 122.08M
Basic EPS
------
Diluted EPS
------
Basic Average Shares
------
Diluted Average Shares
------
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
-¥ 241.31M¥ 282.47M¥ 324.13M¥ 263.94M¥ 242.33M
Net Income From Continuing And Discontinued Operation
-¥ 739.12M¥ 631.81M¥ 81.98M¥ 1.67B¥ 122.08M
Normalized Income
-¥ 220.80M¥ 218.29M¥ 131.13M¥ 105.56M¥ 4.54M
Interest Expense
-¥ 605.00K¥ 10.67M¥ 30.12M¥ 8.61M¥ 0.00
EBIT
-¥ 738.07M¥ 637.27M¥ 115.93M¥ 135.18M¥ 45.08M
EBITDA
-¥ 769.48M¥ 665.71M¥ 145.34M¥ 156.44M¥ 90.98M
Currency in CNY

PW Medtech Group Ltd. Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis